Search Results

Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.

February 28, 2024

·

2 min read

·

Tyler Patchen

Business

Idorsia and Viatris enter into a significant global research and development collaboration

Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.

February 28, 2024

·

9 min read

Press Releases

Idorsia’s once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension

November 18, 2024

·

13 min read

Pictured: Idorsia's office in Switzerland/iStock,

FDA

Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug

Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.

March 21, 2024

·

2 min read

·

Tristan Manalac

Business

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.

February 28, 2024

·

16 min read

Press Releases

Idorsia announces financial results for the first half 2024

July 25, 2024

·

26 min read